Ridloff Elena 4
4 · Kymera Therapeutics, Inc. · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) Director Elena Ridloff Exercises Options, Sells 3,000 Shares
What Happened
Director Elena Ridloff exercised stock options and sold shares on May 11, 2026. The filing shows she acquired 3,000 shares by exercising options at $31.20 per share (cost = $93,600) and sold 3,000 shares in an open-market transaction at $87.00 per share (proceeds = $261,000). The report also lists a 3,000-share derivative disposition at $0.00 (see Key Details).
Key Details
- Transaction date: 2026-05-11.
- Exercise: 3,000 shares exercised at $31.20 (total $93,600).
- Open-market sale: 3,000 shares sold at $87.00 (total proceeds $261,000).
- Derivative entry: 3,000 shares shown as disposed at $0.00 (filing does not specify the reason for the zero-dollar entry).
- Footnotes: Transactions were executed pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 (F1). The options exercised were fully vested and exercisable (F2).
- Shares owned after transaction: not specified in this filing.
- Filing timeliness: Reported and filed with a period of report dated 2026-05-11 (appears filed same day).
Context
This sequence—exercise of options followed by an immediate open-market sale—can reflect a cashless or partially monetized exercise, though the filing itself does not state the exact settlement mechanics. The sale was executed under a pre-established Rule 10b5-1 plan, which generally indicates the transactions were pre-scheduled rather than discretionary trading by the insider on the trade date.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-11$31.20/sh+3,000$93,600→ 3,000 total - Sale
Common Stock
[F1]2026-05-11$87.00/sh−3,000$261,000→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F2]2026-05-11−3,000→ 13,000 totalExercise: $31.20Exp: 2034-06-17→ Common Stock (3,000 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.